
Azacitidine 300 mg (Xpreza) is a prescription oral anticancer medicine used as maintenance treatment for acute myeloid leukaemia (AML) in eligible adults who have achieved remission following previous therapy. It helps control the growth of abnormal blood cells and may prolong remission. Oral azacitidine should be taken exactly as prescribed under the supervision of an oncologist or haematology specialist.
| Generic name | Azacitidine |
| Strength | 300 mg |
| Manufacturer | Natco |
| Package size | 14 Tablets |
| Used for | Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Azacitidine is a hypomethylating medicine that becomes incorporated into the genetic material of abnormal cells. It affects DNA and RNA processes, helps restore the activity of certain genes, and interferes with the growth and survival of cancer cells. These actions help control abnormal blood-cell production and may prolong remission in eligible patients with AML.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.